Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat monotherapy in HER2-positive metastatic breast cancer
2008-003175-45Phase 2Completed
- Sponsor
- TRIO
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panobinostat in breast cancer (2 arms), sponsored by TRIO. Primary endpoints: Objective response rate (investigator assessment) and Objective response rate (independent central review). Started Nov 2008; status: completed.
02
Drugs
panobinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-003175-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003175-45.